G protein β3 polymorphism and triptan response in cluster headache

Clinical Pharmacology and Therapeutics

Volumn 82, Issue 4, 2007, Pages 396-401

  Schurks M ^a   Kurth, T ^b,c   Stude, P ^a   Rimmbach, C ^a   De Jesus, J ^a   Jonjic, M ^a   Diener, H C ^a   Rosskopf, D ^d  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b HARVARD UNIVERSITY   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d UNIVERSITY OF GREIFSWALD   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; ERGOT ALKALOID; GUANINE NUCLEOTIDE BINDING PROTEIN BETA SUBUNIT; LIDOCAINE; LITHIUM; METHYSERGIDE; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; OXYGEN; PREDNISONE; SUMATRIPTAN; TOPIRAMATE; TRIPTAN DERIVATIVE; VALPROIC ACID; VERAPAMIL; DOPAMINE RECEPTOR STIMULATING AGENT; G PROTEIN BETA3 SUBUNIT; G-PROTEIN BETA3 SUBUNIT; HETEROTRIMERIC GUANINE NUCLEOTIDE BINDING PROTEIN; SEROTONIN 1B RECEPTOR; SEROTONIN 1D RECEPTOR; TRYPTAMINE DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; ALLELE; ARTICLE; CAUCASIAN; CLUSTER HEADACHE; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROPHYLAXIS; PROTEIN VARIANT; RISK; STATISTICAL SIGNIFICANCE; TREATMENT RESPONSE; CLINICAL TRIAL; DRUG POTENTIATION; GENE FREQUENCY; GENETICS; GERMANY; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PATIENT SELECTION; PROSPECTIVE STUDY; QUESTIONNAIRE; TREATMENT OUTCOME;

ADULT; CLUSTER HEADACHE; DOPAMINE AGONISTS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENE FREQUENCY; GENOTYPE; GERMANY; HETEROTRIMERIC GTP-BINDING PROTEINS; HETEROZYGOTE; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; PATIENT SELECTION; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES; QUESTIONNAIRES; RECEPTOR, SEROTONIN, 5-HT1B; RECEPTOR, SEROTONIN, 5-HT1D; TREATMENT OUTCOME; TRYPTAMINES;

EID: 34548674210     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/sj.clpt.6100159     Document Type: Article

References (45)

1. Goadsby, P.J., Lipton, R.B. & Ferrari, M.D. Migraine - current understanding and treatment. N. Engl. J. Med. 346, 257-270 (2002).
2. Sanders-Bush, S. & Mayer, S.E. 5-Hydroxytryptamine (serotonin) receptor agonists and antagonists in Goodman & Gilman's The Pharmacological Basis of Therapeutics (ed. Brunton, L.L., Lazi, J.S. & Parker, K.L.) 297-315 McGraw Hill, New York, (2005).
3. May, A. Cluster headache: pathogenesis, diagnosis, and management. Lancet 366, 843-855 (2005).
4. The Sumatriptan Cluster Headache Study Group. Treatment of acute cluster headache with sumatriptan. N. Engl. J. Med. 325, 322-326 (1991).
5. van Vliet, J.A. et al. Intranasal sumatriptan in cluster headache: randomized placebo-controlled double-blind study. Neurology 60, 630-633 (2003).
6. Schuh-Hofer, S. et al. Treatment of acute cluster headache with 20 mg sumatriptan nasal spray - an open pilot study. J. Neurol. 249, 94-99 (2002).
7. Bahra, A. et al. Oral zolmitriptan is effective in the acute treatment of cluster headache. Neurology 54, 1832-1839 (2000).
8. Lipton, R.L. & Bigal, M.E. Migraine: epidemiology, impact, and risk factors for progression. Headache 45, S3-S13 (2005).
9. Headache Classification Subcommittee of the International Headache Society. The international classification of headache disorders, 2nd edition. Cephalgia 24(Suppl 1): 9-160 (2004).
10. Oleson, J. et al. Calcitonin-gene related peptide antagonist BIBN 4096BS for the acute treatment of migraine. N. Engl. J. Med. 350, 1104-1110 (2004).
11. Diener, H.C. et al. Placebo-controlled comparison of effervescent acetylsalicylic acid, sumatriptan and ibuprofen in the treatment of migraine attacks. Cephalalgia 24, 947-954 (2004).
12. Dodick, D.W. et al. Cluster headache. Cephalalgia 20, 787-803 (2000).
13. 2C, and hSERT polymorphisms. Headache 44, 311-317 (2004).
14. Zgombick, J.M. et al. Dual coupling of cloned human 5-hydroxytryptamine1D alpha and 5-hydroxytryptamine1D beta receptors stably expressed in murine fibroblasts: inhibition of adenylate cyclase and elevation of intracellular calcium concentrations via pertussis toxin-sensitive G protein(s). Mol. Pharmacol. 44, 575-582 (1993).
15. i family. Br. J. Pharmacol. 136, 1072-1078 (2002).
16. 1D receptors in sumatriptan mediated vasocontractile response in rabbit common artery. Br. J. Pharmacol. 136, 177-182 (2000).
17. Siffert, W. et al. Association of a human G-protein β3 subunit variant with hypertension. Nat. Genet. 18, 45-48 (1998).
18. Zill, P. et al. Evidence for an association between a G-protein β3 gene variant with depression and response to antidepressant treatment. Neuroreport 11, 1893-1897 (2000).
19. Nürnberger, J. et al. Effect of the C825T polymorphism of the G protein β3 subunit on the systolic blood pressure-lowering effect of clonidine in young, healthy male subjects. Clin. Pharmacol. Ther. 74, 53-60 (2003).
20. Hauner, H. et al. Prediction of successful weight reduction under sibutramine therapy through genotyping of the G-protein β3 subunit gene (GNB3) C825T polymorphism. Pharmacogenetics 13, 453-459 (2003).
21. Mitchell, A. et al. Venous response to nitroglycerin is enhanced in young, healthy carriers of the 825T allele of the G protein β3 subunit gene (GNB3). Clin. Pharmacol. Ther. 74, 499-504 (2003).
22. Lee, H.J. et al. Association between a G-protein β3 subunit gene polymorphism and the symptomatology and treatment responses of major depressive disorders. Pharmacogenomics J. 4, 29-33 (2004).
23. Muller, D.J. et al. Suggestive association between the C825T polymorphism of the G-protein β3 subunit gene (GNB3) and clinical improvement with antipsychotics in schizophrenia. Eur. Neuropsychopharmacol. 15, 525-531 (2005).
24. Siffert, W. et al. Worldwide ethnic distribution of the G protein β3 subunit 825T allele and its association with obesity in Caucasian, Chinese, and Black African individuals. J. Am. Soc. Nephrol. 10, 1921-1930 (1999).
25. Rosskopf, D., Manthey, I. & Siffert, W. Identification and ethnic distribution of major haplotypes in the gene GNB3 encoding the G-protein β3 subunit. Pharmacogenetics 12, 209-220 (2002).
26. Evans, D.C. et al. Eletriptan metabolism by human hepatic CYP450 enzymes and transport by human P-glycoprotein. Drug Metab. Dispos. 31, 861-869 (2003).
27. Gueorguieva, I., Nestorov, I.A., Aarons, L. & Rowland, M. Uncertainty analysis in pharmacokinetics and pharmacodynamics: application to naratriptan. Pharm. Res. 22, 1614-1626 (2005).
28. Sternieri, E. et al. Pharmacokinetics of sumatriptan in non-respondent and in adverse drug reaction reporting migraine patients. J. Headache Pain 6, 319-321 (2005).
29. 1B/1D receptor agonists. Proc. Natl. Acad. Sci. USA 101, 4274-4279 (2004).
30. Fogan, L. Treatment of cluster headache. A double-blind comparison of oxygen vs air inhalation. Arch. Neurol. 42, 362-363 (1985).
31. Couch, J.R. & Ziegler, D.K. Prednisone therapy for cluster headache. Headache 17, 219-221 (1978).
32. Leone, M. et al. Verapamil in the prophylaxis of episodic cluster headache: a double-blind study versus placebo. Neurology 54, 1382-1385 (2000).
33. Schürks, M. et al. Cluster headache is associated with the G1246A polymorphism in the hypocretin receptor 2 gene. Neurology 66, 1917-1919 (2006).
34. Rosskopf, D. et al. Identification and characterization of Gβ3s2, a novel splice variant of the G-protein β3 subunit. Biochem. J. 371, 223-232 (2003).
35. Rosskopf, D. et al. Interaction of Gβ3s, a splice variant of the G-protein Gβ3, with Gα- and Gγ-proteins. Cell. Signal. 15, 479-488 (2003).
36. i proteins as aetiopathogenic mechanism for migraine and cluster headache. Cephalalgia 21, 38-45 (2001).
37. Holtmann, G. et al. G-protein β3 subunit 825 CC genotype is associated with unexplained (functional) dyspepsia. Gastroenterology 126, 971-979 (2004).
38. Prestes, A.P. et al. The GNB3 C825T polymorphism and depression among subjects with alcohol dependence. J. Neural. Transm. [E-pub ahead of print] DOI 10.1007/s00702-006-0550-2 (2006).
39. Mitchell, A., Rushentsova, U., Siffert, W., Philipp, T. & Wenzel, R.R. The angiotensin II receptor antagonist valsartan inhibits endothelin 1-induced vasoconstriction in the skin microcirculation in humans in vivo: influence of the G-protein β3 subunit (GNB3) C825T polymorphism. Clin. Pharmacol. Ther. 79, 274-281 (2006).
40. Mitchell, A. et al. Insulin-mediated venodilation is impaired in young, healthy carriers of the 825T allele of the G-protein β3 subunit gene (GNB3). Clin. Pharmacol. Ther. 77, 495-502 (2005).
41. Mitchell, A. et al. Effects of systemic endothelin A receptor antagonism in various vascular beds in men: in vivo interactions of the major blood pressure-regulating systems and associations with the GNB3 C825T polymorphism. Clin. Pharmacol. Ther. 76, 396-408 (2004).
42. Sarchielli, P. et al. Clinical-biochemical correlates of migraine attacks in rizatriptan responders and non-responders. Cephalalgia 26, 257-265 (2006).
43. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgia, and facial pain. Cephalalgia 8, 1-96 (1988).
44. Schürks, M. et al. Cluster headache: clinical presentation, lifestyle features, and medical treatment. Headache 46, 1246-1254 (2006).
45. Schürks, M. et al. The G1246A polymorphism in the hypocretin receptor 2 gene and treatment response in cluster headache. Cephalalgia (in press).